World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Patricia Carr Biography and Net Worth

SVP of Jazz Pharmaceuticals

Patricia Carr serves as Vice President, Finance and Principal Accounting Officer of the Company. Prior to that, from September 2011 to July 2012, she served as Vice President, Finance of Alkermes plc, a global biopharmaceutical company. From June 2002 to September 2011, she served in a number of roles in Elan Corporation, a neuroscience-based biotechnology company, most recently as Vice President, Finance.

What is Patricia Carr's net worth?: The estimated net worth of Patricia Carr is at least $898,544.52 as of March 6th, 2024. Ms. Carr owns 8,364 shares of Jazz Pharmaceuticals stock worth more than $898,545 as of April 25th. This net worth approximation does not reflect any other assets that Ms. Carr may own. Learn More about Patricia Carr's net worth.
How old is Patricia Carr?: Ms. Carr is currently 52 years old. There are 4 older executives and no younger executives at Jazz Pharmaceuticals. The oldest executive at Jazz Pharmaceuticals is Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO, who is 60 years old. Learn More on Patricia Carr's age.
How do I contact Patricia Carr?: The corporate mailing address for Ms. Carr and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Patricia Carr's contact information.
Has Patricia Carr been buying or selling shares of Jazz Pharmaceuticals?: Patricia Carr has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Patricia Carr sold 1,936 shares of the business's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a transaction totalling $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. Learn More on Patricia Carr's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 3/6/2024.

Patricia Carr Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2024	Sell	1,936	$119.64	$231,623.04	8,364
8/29/2023	Sell	142	$143.47	$20,372.74	5,986
8/14/2023	Sell	158	$138.16	$21,829.28	6,128
6/7/2023	Sell	126	$127.92	$16,117.92	6,286
3/15/2023	Sell	1,023	$133.22	$136,284.06	6,286
3/5/2023	Sell	1,148	$140.76	$161,592.48	7,309
12/5/2022	Sell	63	$152.06	$9,579.78	5,934
8/15/2022	Sell	2,142	$160.06	$342,848.52	5,934
5/11/2022	Sell	722	$147.51	$106,502.22	6,234
5/9/2022	Sell	1,067	$148.94	$158,918.98	7,229
8/6/2021	Sell	157	$147.96	$23,229.72	6,035
12/4/2020	Sell	62	$152.55	$9,458.10
8/12/2020	Sell	142	$123.80	$17,579.60	6,200
8/7/2020	Sell	158	$125.87	$19,887.46	6,342
6/5/2020	Sell	138	$124.00	$17,112.00
3/12/2020	Sell	600	$102.17	$61,302.00	6,500
3/9/2020	Sell	568	$111.45	$63,303.60	7,668
3/6/2020	Sell	232	$119.17	$27,647.44	7,668
3/3/2020	Sell	247	$119.75	$29,578.25	8,153
12/5/2019	Sell	1,749	$148.93	$260,478.57

Patricia Carr Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $107.43

$107.22

$109.05

50 Day Range

MA: $118.98

$107.10

$132.77

2 Week Range

Now: $107.43

$106.61

$146.70

Volume

423,801 shs

Average Volume

606,011 shs

Market Capitalization

$6.77 billion

P/E Ratio

17.55

Dividend Yield

N/A

Beta

0.59

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Click here to find out what to do.

Patricia Carr Biography and Net Worth

What is Patricia Carr's net worth?

How old is Patricia Carr?

How do I contact Patricia Carr?

Has Patricia Carr been buying or selling shares of Jazz Pharmaceuticals?

Who are Jazz Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Jazz Pharmaceuticals?